VantAI pairs bleeding-edge machine learning techniques with deep systems biology expertise to build computational models that uncover hidden relationships between molecules, targets, and diseases. These models power a best-in-class solution that identifies and generates new molecular entities for targets of interest, repurposes existing molecules at any stage of development, uncovers accurate ADME and toxicological insights, and predicts adverse events likely to influence trial success from deep analysis of systems-based pharmacogenomics. VantAI's in silico platform specializes in modelling complex protein-protein interactions, powering the discovery of biologics and protein degraders in addition to small-molecule drugs. It has helped leading biopharma partners launch new development programs--or revitalize old ones--at a fraction of the time and cost of traditional methods. For more information, please visit http://www.vant.ai.
Location: United States, New York
Employees: 11-50
Founded date: 2019
Investors 1
| Date | Name | Website |
| 21.08.2023 | Roivant | roivant.co... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 30.11.2021 | Swiss deeptech startups dominate Forbes 30under30 DACH | Every year, Forbes’ 30under30 list identifies and honours individuals whose initiatives, innovativ... | startuptic... |
| 09.12.2020 | South Korean conglomerate injects $200 million in Roivant | Roivant Sciences develops medicines by leveraging the Roivant platform to launch "Vants" –... | startuptic... |
| 09.12.2020 | South Korean conglomerate injects $200 million in Roivant | Roivant Sciences develops medicines by leveraging the Roivant platform to launch "Vants"... | startuptic... |